novartis
Swiss pharma giant Novartis on Thursday reported more than 40% growth in profit in the second quarter, primarily driven by strong sales for a few key drugs. Novartis also raised its full-year core operating income guidance. Net income for the second quarter was $3.2 billion, up from $2.2 billion in the same quarter a year ago. Operating income rose 43% to $4 billion from a year ago. Revenue for the quarter grew 9% to $12.5 billion. The company's top two drugs - Entresto, which is used to treat patients with heart failure, and Cosentyx, for psoriasis and arthritis - raked in $1.9 billion and $1...
DPA
Swiss pharmaceutical giant Novartis saw its shares jump after reporting solid first-quarter profits and sales growth on Tuesday. Shares were up more than 4% in Switzerland and more than 5% in pre-market activity in New York. The company also raised its fiscal 2024 outlook for growth in sales and core operating income. Further, Novartis said it plans to propose Giovanni Caforio as chair of the board of directors at its annual general meeting in 2025. The 12-year term of Joerg Reinhardt is set to end as scheduled in 2025, when he will retire and not be available for re-election. Novartis chief e...
DPA
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら